These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37824367)

  • 1. The Mutational and Transcriptional Landscapes of Speckle-Type POZ Protein (SPOP) and Androgen Receptor (AR) in a Single-Center pT3 Prostatectomy Cohort.
    Eryilmaz IE; Vuruskan BA; Kaygisiz O; Cecener G; Egeli U; Vuruskan H
    J Environ Pathol Toxicol Oncol; 2024; 43(1):15-29. PubMed ID: 37824367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
    García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
    Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G3BP1 inhibits Cul3
    Mukhopadhyay C; Yang C; Xu L; Liu D; Wang Y; Huang D; Deonarine LD; Cyrta J; Davicioni E; Sboner A; Robinson BD; Chinnaiyan AM; Rubin MA; Barbieri CE; Zhou P
    Nat Commun; 2021 Nov; 12(1):6662. PubMed ID: 34795264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
    An J; Wang C; Deng Y; Yu L; Huang H
    Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Speckle-type POZ protein mutations interrupt tumor suppressor function of speckle-type POZ protein in prostate cancer by affecting androgen receptor degradation.
    Lai J; Batra J
    Asian J Androl; 2014; 16(5):659-60. PubMed ID: 24969063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
    Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
    APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of speckle-type POZ protein somatic mutations in African American prostate cancer.
    Buckles E; Qian C; Tadros A; Majumdar S; Cvitanovic J; Zabaleta J; Estrada J; Wilson J; Liu W
    Asian J Androl; 2014; 16(6):829-32. PubMed ID: 24994784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
    Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
    Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
    Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
    Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
    Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
    Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
    Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
    Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the SPOP mutant genomic subclass in prostate cancer.
    Shoag J; Liu D; Ma X; Oromendia C; Christos P; Ballman K; Angulo C; Cai PY; Gaffney C; Klein E; Karnes J; Den RB; Liu Y; Davicioni E; Barbieri CE
    Urol Oncol; 2020 May; 38(5):418-422. PubMed ID: 32192889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
    Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
    Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
    Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
    Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
    Fong KW; Zhao JC; Song B; Zheng B; Yu J
    Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.
    Grbesa I; Augello MA; Liu D; McNally DR; Gaffney CD; Huang D; Lin K; Ivenitsky D; Goueli R; Robinson BD; Khani F; Deonarine LD; Blattner M; Elemento O; Davicioni E; Sboner A; Barbieri CE
    Cell Rep; 2021 Sep; 36(10):109625. PubMed ID: 34496233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification of speckle type BTB/POZ protein mutation regulated key metabolic pathways by cell based proteomics and metabolomics].
    Yan M; Liu J; Xia T; Xu G; Piao H
    Se Pu; 2019 Aug; 37(8):887-896. PubMed ID: 31642260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.